C2N Diagnostics partners with The Michael J. Fox Foundation to uncover new links between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease. Over $1.5 million from the foundation will help C2N Diagnostics R&D better understand the connections amongst neurodegenerative conditions. The finding will allow C2N researchers to connect research fluid samples and novel fluid biomarker test results to better understand the interplay between the diseases.

The first phase of the initiative involves MJFF’s Parkinson’s Progression Markers Initiative (PPMI) using C2N’s PrecivityAD2™ blood test, which will aid researchers in their studies to detect amyloid plaques in the brain, which is a pathological hallmark of Alzheimer’s Disease.

The researchers also will use C2N’s proprietary biomarker test that can measure the microtubule binding region of tau (MTBR-tau), which is specific for neurofibrillary “tau” tangles that help diagnose and stage Alzheimer’s Disease.